InsidersTradesSigma
Total declarations
Company
▲ Purchases (4 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
4
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-16.3%
Across 4 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the complete record of transactions filed by Butler Thomas Andrew, Chief Executive Officer. Director active across 1 company, notably Biomea Fusion, Inc.. In total, 4 reports have been published. Breakdown: 4 buys · 0 sell. Total volume traded: €5.6m. History available since 15 April 2021. The latest transaction was disclosed on 23 August 2021 (Acquisition). Regulator: SEC (Form 4). The full history is free.
Declarations4 total
24,000 shares@ US$13.2030.28% mcap4.9% of flowCommon StockSEC:0001567619-21-016341:0
Ideal exit: 20 May 2022 (T+270)
24,000 shares@ US$13.2034.9% of flowCommon StockSEC:0001567619-21-016341
Ideal exit: 20 May 2022 (T+270)
176,470 shares@ US$17.0045.1% of flowCommon StockSEC:0001567619-21-016159
Ideal exit: 10 Jan 2022 (T+270)
176,470 shares@ US$17.002.57% mcap45.1% of flowCommon StockSEC:0001567619-21-016159:0
Ideal exit: 10 Jan 2022 (T+270)
4 of 4 declarations
About Butler Thomas Andrew
Thomas Andrew Butler is the Chief Executive Officer of Biomea Fusion, Inc. He is responsible for the strategic and operational direction of the company. His role is essential in ensuring growth and innovation in the pharmaceutical sector.
